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ABSTRACT 
 
Objective: To evaluate the long-term response to antiretroviral treatment (ART) based on 
atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing 
regimens. 
Methods: Data were analyzed from 5,678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r-, and LPV/r-
containing regimens between 1 January 2000 and 30 June 2013. Separate analyses were performed for 
the following subgroups of patients: (a) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor 
(PI/r) initiation; (b) ART-experienced individuals (44%) initiating the new PI/r with viral load (VL) ≤500 
copies/mL; and (c) ART-experienced patients (48%) initiating the new PI/r with VL >500 copies/mL. 
Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL after ≥24 weeks 
of PI/r initiation. Kaplan-Meier and multivariable Cox models were used to compare the risk of failure by 
PI/r-based regimens. The main analysis was performed by intention-to-treat (ITT) ignoring treatment 
switches. 
Results: The time to VF favored DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test, P <0.02) 
in all analyses. Nevertheless, the risk of VF in ART-naïve patients was similar regardless of the PI/r initiated 
after controlling for potential confounders. The risk of VF in both treatment-experienced groups was 
lower in DRV/r than in ATZ/r, which, in turn, was lower than in LPV/r-based ART.  
Conclusions: Although confounding by indication and calendar year cannot be completely ruled out, in 
ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be 
greater than that of ATZ/r and LPV/r. 
 
Keywords: Darunavir/ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, naïve-patients, ART-experienced 
patients.  
Introduction 
The new global 90-90-90 WHO targets call for 90% of all people with HIV to be diagnosed, 90% of people 
with HIV diagnosis to be treated, and 90% of treated subjects to have virological suppression by 2020 [1]. 
Standard antiretroviral treatment (ART) is still based on a combination of at least 3 antiretroviral drugs 
[2–4], it is generally expensive, and there are still many limitations to its use, especially in developing 
countries. 
Consistent with ART optimizing principles, availability of fixed-dose combinations, tolerability, and the risk 
of resistance mutations, recent WHO recommendations for the limited resource setting include the use 
of non-nucleoside reverse transcriptase inhibitors and integrase strand-transfer inhibitors in first-line ART, 
and darunavir/ritonavir (DRV/r), lopinavir/ritonavir (LPV/r), and atazanavir/ritonavir (ATZ/r) as alternative 
drugs in second and third ART regimens [1]. Nevertheless, these drugs have different profiles of efficacy, 
safety, and tolerability [5–8].  
Because the effectiveness of therapy in daily clinical practice usually differs from what is observed in 
clinical trials [9,10], it is important to analyse the experience with use of DRV/r, ATZ/r, and LPV/r in 
unselected HIV-infected patients. This study aimed to evaluate the long-term effectiveness of DRV/r-, 
ATZ/r-, and LPV/r-containing regimens initiated at various stages during participants’ antiretroviral 
treatment history and the factors associated with virological failure (VF), treatment discontinuation, and 
CD4 cell count recovery in a large European cohort of HIV-1-infected patients.  
 
Methods 
Study population and data collection 
The EuroSIDA study is a prospective, observational cohort of more than 22,000 HIV-positive subjects in 
105 centers in 35 European countries, Israel, and Argentina, which has been described in detail previously 
[11,13–15]. The study population of the present analysis included all EuroSIDA-enrolled patients initiating 
an ATZ/r-, DRV/r-, or LPV/r-containing regimen between 1 January 2000 and 30 June 2013 who also had 
at least one additional clinical visit. Patients were included if they satisfied the inclusion criteria for one of 
the following groups: (a) ART-naive, i.e., previously untreated subjects at the time of boosted protease 
inhibitor (PI/r) initiation; (b) ART-switching, i.e., ART-experienced individuals initiating the new PI/r with 
VL ≤500 copies/mL; and (c) ART-salvage, i.e., ART-experienced patients initiating the new PI/r with VL >500 
copies/mL, including patients who were on voluntary ART-interruption. Prior exposure to PI/r was 
allowed. Data were collected at the date of DRV/r, ATZ/r, or LPV/r initiation (baseline) and during the 
follow-up period, according to the EuroSIDA study protocol. Data collected for this analysis included 
demographic characteristics (age, gender, ethnicity, route of HIV-infection transmission), AIDS stage at 
time of PI/r initiation, hepatitis C and B virus (HCV/HBV) co-infections, HIV-1 RNA levels, CD4+ cell counts, 
CD4+ nadir at baseline, number of previous failures of treatment to specific drug classes, previous 
exposure to PI, nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbones included in PI/r regimen, 
and genotypic test results performed before DRV/r, ATZ/r, or LPV/r initiation (when available). 
The primary endpoint of this analysis was the median time to VF after DRV/r, ATZ/r, or LPV/r initiation. VF 
was defined as two consecutive VL ≥200 copies/mL at 24 weeks or at any time after achieving HIV-1 RNA 
≤50 copies/mL. The date of the first VL ≥200 copies/mL was used to define the time at which VF had 
occurred. The secondary endpoints were time to the composite endpoint of VF or PI/r discontinuation, 
and time to achieve a gain of CD4+ T cell count ≥200 cells/mm3 above baseline levels while the person 
remained with a viral load ≤200 copies/mL. 
Prior approval was given by the Ethics Committee of each participating center for the study, which is being 
carried out according to the stipulations of the Declaration of Helsinki (Seoul, 2008). All patients gave their 
written informed consent prior to participation. 
 
Statistical analysis  
For descriptive purposes, Europe was divided into six regions: north (Denmark, United Kingdom, Ireland, 
the Netherlands, Norway, Finland, and Sweden); east (Belarus, Estonia, Latvia, Lithuania, Russia, and 
Ukraine); west central (Austria, Belgium, France, Germany, Luxembourg, and Switzerland); east central 
(Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, and Slovakia); and south (Greece, 
Italy, Spain, Portugal, and Israel). Argentina was analyzed separately. Variables with a normal distribution 
were described as mean (SD) and compared using the t-test. Median and IQR were used to describe 
variables that did not follow a normal distribution, which were compared using a non-parametric test. 
Percentages were compared using the X2 test or an exact binomial test when appropriate. Separate 
analyses were performed in the ART-naïve and each of the two ART-experienced groups.  
Kaplan-Meier analysis was used to determine the median time to VF and the proportion of patients who 
experienced VF up to five years from starting the PI/r-based regimen. Hazard ratios (HR) and 95% 
confidence intervals (95% CI) were calculated and a proportional hazards Cox regression model was 
performed to identify factors associated with each of the three considered outcomes. Multivariable 
models were fitted using 0.05 as the significance level in univariable analysis for a covariate to be included 
in the final multivariable model. The relationship between the final set of included covariates was checked 
and removed when collinearity was detected. Effectiveness was evaluated by an intention to treat (ITT) 
analysis ignoring treatment switches of PI/r (genuine ITT analysis). Sensitivity analyses were performed 
with any discontinuation of PI/r counted as failure (ITT: Switching=Failure; ITT: S=F), counting as failures 
only discontinuations of PI/r due to toxicity (ITT: switch for Toxicity=Failure; ITT: T=F), and with data 
censored at the date of PI/r discontinuation (on-treatment analysis, OT). In addition, in the pre-treated 
population subgroup that had initiated the new PI/r-containing regimen with VL >500 copies/mL, 
sensitivity analyses were also performed on those subjects initiating PI/r after 2004 and with genotyping 
tests available. 
Statistical analysis was performed using SAS (Statistical Analysis Software, Cary, NC, USA, version 9.3).  
 
Results 
A total of 5,678 out of 18,913 HIV-infected individuals enrolled in the EuroSIDA study up to September 
30, 2013, met the inclusion criteria for this analysis.  
 
ART-naïve subgroup 
Of these 5,678, a total of 431 (8%) were ART-naïve patients of which 220 (51%) were receiving LPV/r, 119 
(28%) were on ATZ/r, and 92 (21%) were on DRV/r-based regimens. The median (IQR) time of follow-up 
was 28 (11-57) months. Table 1 presents the baseline characteristics of this subgroup of patients. Median 
(IQR) CD4+ cell counts and HIV VL were 261 (164-352) cells/mm3 and 79,271 (780-8,415,274) copies/mL, 
respectively. Genotypic resistance tests before PI/r initiation were available for 111 (26%) subjects.  
Of the 431 patients included, 79 (18%) experienced VF during the follow-up. Of the 184 (42.7%) subjects 
with the composite endpoint of VF or PI/r discontinuation, PI/r was discontinued in 148 (80.4%). In the 
genuine ITT analysis, the median time to VF was longer (log rank, p = 0.004) for patients who initiated 
DRV/r-based treatment in comparison to those patients initiating ATZ/r or LPV/r (Figure 1A). Similarly, 
patients initiating DRV/r also had the longest median time to failure compared to ATZ/r or LPV/r in the 
ITT: S=F and ITT: T=F sensitivity analyses (Figures 1B and 1C), but not in the OT analysis (supplementary 
data, Figure 1A). 
After adjustment for confounding variables, the multivariable Cox proportional hazard model showed no 
differences between DRV/r, ATZ/r, or LPV/r in the ITT analysis and when we examined the composite 
endpoint of VF or PI/r discontinuation (Figure 1D). Nevertheless, patients with AIDS diagnosis at time of 
initiation of their first PI/r-based ART were significantly more likely to experience VF (HR: 2.97, 95% CI: 
1.26-7.03, p = 0.01), and female gender (vs male HR: 2.08, 95% CI: 1.20-3.63, p = 0.01 were associated 
with a higher risk in the ITT: S=F sensitive analysis (supplementary data, Figure 2). 
No differences were found with regard to the probability of gaining a CD4+ cell count ≥200 cells/mm3 in 
the Cox proportional hazard model (Figure 1D) when comparing the three PI/r treatment groups.  
 
ART-switching subgroup 
A total of 2,507 (44%) subjects had been switched to DRV/r, ATZ/r, or LPV/r with HIV VL ≤500 copies/mL. 
Of these, 1031 (41%) started a LPV/r-based, 824 (33%) started an ATZ/r-based, and 652 (26%) started a 
DRV/r-based regimens. The median (IQR) time of follow-up was 40 (17-68) months, and the median (IQR) 
CD4+ cell count was 468 (317-652) cells/mm3. The median (IQR) number of previous PI previously 
experienced was 2 (1-3) and historical genotypic resistance tests before switching to PI/r were available 
for 1171 (47%) patients (Table 2). The median (IQR) duration of continuous viral suppression prior to 
baseline was 56 (32-84) months.  
Out of the 2,507 patients included in this subgroup, 408 (16%) experienced VF during the follow-up. Of 
the 1278 (51.0%) subjects with the composite endpoint, PI/r was discontinued in 1042 (81.5%). In the ITT 
analysis, the median time to VF was longer (log rank, p <0.0001) for patients who initiated a DRV-switch 
strategy (Figure 2A), with a risk of developing VF of 5.8% [95% CI 3.6, 8.0] by 3 years compared to those 
who initiated ATZ/r (13.8 % [95% CI 11.4, 16.3]) or LPV/r (21.1 % [95% CI 18.5, 23.7]). Similar differences 
were observed in the sensitivity ITT: S=F, ITT: T=F, and OT analyses (Figures 2B, 2C, and supplementary 
Figure 1B, respectively).  
Switching to LPV/r (HR: 2.56; 95% CI 1.62, 4.05; p <0.001) or ATZ/r (HR: 1.98; 95% CI 1.27, 3.08; p <0.001) 
was associated with a higher risk of VF in comparison to DRV/r in the multivariable Cox proportional 
hazard model according to the ITT analysis (Figure 2D). In addition, intravenous drug use, higher HIV-1 
RNA at baseline, black ethnicity, having historic genotyping tests available, and number of prior failures 
to non-PI based ART were independent predictors of an increased hazard of VF. The association with 
baseline VL was confirmed when it was explored using a categorical variable (ARH: 1.64; 95% CI 1.22, 2.21; 
p = 0.001 and ARH: 1.87; 95% CI 1.39, 2.53; p <0.001 comparing the VL≤ 50 copies/mL stratum with 51-
200 and 201-500 copies/mL, respectively). By contrast, younger patients, with higher CD4+ cell count at 
switching, and having initiated DRV/r, ATZ/r, or LPV/r more recently were all associated with a lower 
hazard of VF (supplementary data, Figure 4).  
The use of DRV/r, ATZ/r, or LPV/r, however, was not found to be predictive of CD4 count response in the 
multivariable Cox proportional hazard model (Figure 2D).  
 
ART-salvage subgroup 
A total of 2,740 (48%) patients began DRV/r, ATZ/r, or LPV/r with HIV-1 RNA ≥500 copies/mL. Of these, 
1,893 (69%) started a LPV/r-based, 594 (22%) started an ATZ/r-based, and 253 (9%) started a DRV/r-based 
regimens. Their median (IQR) time of follow-up was 35 (12-72) months. Median (IQR) CD4+ cell counts 
and HIV VL were 260 (156-380) cells/mm3 and 31,482 (501-7,943,282) copies/mL, respectively. The 
median (IQR) number of PI previously experienced was 2 (1-3) and genotypic resistance tests were 
available for 1,268 (46%) subjects (Table 2).  
Out of the 2,740 patients included, 942 (34%) experienced VF during the follow-up. Of the 1812 (66%) 
subjects with the composite endpoint, PI/r was discontinued in 1267 (70%). In the ITT analysis, the median 
time to VF was longer (log rank, p <0.001) for patients who initiated DRV/r-based treatment as salvage 
ART-regimen (Figure 3A), with a risk of developing VF of 14.2% (95% CI 8.6, 19.9) by 3 years compared to 
patients who initiated ATZ/r (20.6% [95% CI 17.1, 24.1]) or LPV/r (37.9% [95% CI 35.6, 40.2]). Similarly, 
patients initiating DRV/r also showed longer time to failure compared to those initiating ATZ/r or LPV/r in 
sensitivity analyses (Figures 3B, 3C and supplementary data: Figure 1C), and in the analyses restricted to 
subjects with a pre-treatment genotype available (supplementary data, Figure 5) or initiating boosted PI 
after 2004 (supplementary data, Figure 6).  
In addition, patients who initiated LPV/r- (HR: 1.61; 95% CI 1.02, 2.54; p = 0.040) had a higher risk of VF 
than those who initiated DRV/r in the multivariable Cox proportional hazard model (Figure 3D). 
Furthermore, having acquired HIV infection through heterosexual sex (compared to men who have sex 
with men, higher HIV-1 RNA at salvage regimen initiation, and number of prior failures to respond to PI/r-
based ART were associated with increased risk of VF. By contrast, younger patients, higher CD4+ cell count 
at ART-rescue, and having started DRV/r, ATZ/r, or LPV/r in more recent years were associated with a 
lower hazard of VF (supplementary data, Figure 7).  
When we examined the composite endpoint of VF or PI/r discontinuation, starting LPV/r- or ATZ/r-based 
regimens as salvage ART was associated with a higher risk (HR: 3.12, 95% CI: 2.28-4.28, p <0.001 and HR: 
2.09, 95% CI:1.52-2.88, p <0.001, respectively) than DRV/r in the ITT: S=F sensitive analysis. Similar results 
were also observed in the ITT: T=F (supplementary data, Figure 7). 
The use of DRV/r, ATZ/r, or LPV/r was not found to be predictive of CD4 count response in the 
multivariable Cox proportional hazard model (Figure 3D), although a higher CD4 nadir, HIV RNA, and the 
availability of a genotyping test were all factors associated with a better chance of CD4 count recovery 
(supplementary data, Figure 3).  
 
Discussion 
In this analysis, when we examined endpoints that counted PI/r discontinuation as treatment failures, 
there was a clear superiority of DRV/r over LPV/r and ATZ/r. Indeed, although the risk of VF was similar in 
DRV/r, ATZ/r, and LPV/r in ART-naïve patients, the risk of PI/r discontinuation due to any reason was 
lowest for DRV/r. In the treatment-experienced patients who initiated PI/r either as the result of a 
switching strategy with suppressed viral load or as a salvage treatment, patients who experienced VF and 
the risk of VF or PI/r discontinuation was lower for DRV/r- compared to both LPV/r and ATZ/r. 
In ART-naïve patients, the antiviral efficacy of ATZ/r has been shown to be similar to that of DRV/r and 
LPV/r in randomized studies [5,16,17]. However, ATZ/r shows higher rates of jaundice and 
hyperbilirrubinemia than DRV/r and LPV/r [5,17], a worse lipid profile than DRV/r [16,18], albeit with less 
gastrointestinal toxicity, and a better lipid profile than LPV/r. 5 In addition, DRV/r is superior to LPV/r in 
virological response [19], with a higher genetic barrier [6,20], higher efficacy in patients of different 
gender, age, race, or co-infection status [21], and fewer discontinuations due to adverse events [6]. In our 
analysis, we found no significant differences in the risk of VF between the three drugs. It must be noted, 
however, that the number of VF events was especially small with DRV/r, so the analysis of the ART-naïve 
population was likely underpowered. In contrast and coinciding with literature [6,17], we observed that 
the risk of PI/r discontinuation for any reason was >2.5 times higher in patients who started LPV/r- than 
in those initiating a DRV/r-based ART, while no significant difference was observed when ATZ/r and DRV/r 
regimens were compared. In addition, the study design and limited number of ART-naïve patients, 
including those with HIV VL >100,000 copies/mL and low CD4 cell count levels, might partly explain why 
prior AIDS diagnosis and female gender, but not the recognized CD4 cell count and HIV-RNA, were 
identified as predictive factors of virological response and clinical outcomes in ART-naïve patients [22–
25]. Therefore, we believe that these results should be interpreted with caution.  
In treatment-experienced patients, DRV/r and ATZ/r have been shown to be suitable for switching 
strategies with suppressed viral load [26–29], while DRV/r has been demonstrated to be the most 
effective PI/r in ART salvage strategies [7,30,31]. Regarding LPV/r, its posology, as well as a worse 
tolerance profile compared to DRV/r and ATZ/r [5,6],  currently make it difficult to use in switching 
strategies. Nevertheless, LPV/r continues to have a role in second-line regimens in resource-limited 
settings [1]. Consistently, our results show a lower risk of experiencing VF and treatment discontinuation 
for any reason or due to toxicity in patients starting DRV/r compared to those initiating ATZ/r or LPV/r, 
reflecting the well-known better efficacy and safety profile of DRV/r, and of ATZ/r compared with LPV/r-
based regimens ]5–7]. However, confounding by indication for switching cannot be ruled out.  
As expected, having genotyping tests available and the number of prior failures of treatment with non-PI 
and PI-based ART were identified as predictors of virological response in patients from both subgroups of 
treatment-experienced patients. Having a history of genotypic testing might be considered a proxy of poor 
adherence or reflect selected testing for people perceived at increased risk of detection of resistance and 
risk of failure. Other characteristics such as age (older patients), female gender, men who have sex with 
women, black ethnicity, and co-infection with HCV were also identified in our study as factors associated 
with the risk of VF and treatment discontinuation in the ART-experienced patients. Similar results have 
been previously reported [24,32–39], and they may be the result of confounding due to differences in 
sociodemographic characteristics [35].  
Our analysis has a number of limitations. First, we cannot rule out confounding by indication and calendar 
year as our patients were not randomized to the evaluated strategies. One crucial unmeasured possible 
confounder is indeed ART adherence, which has been shown to guide treatment choices and to be a 
predictor of treatment response and survival in HIV-infected patients [40,41]. Moreover, the better 
tolerance profile as well as the once daily dosage could have favored a better adherence of DRV/r and 
ATV/r compared to LPV/r [5,6]. Secondly, participants were from multiple countries showing a great 
diversity of socioeconomic and demographic characteristics, as well as differences in access to care, 
medical insurance, prevalence of immigration, co-morbidities and incidence of mental health disorders in 
PWID patients, pharmacokinetic or pharmacodynamic factors, and composition of the ART, some of which 
we tried to control for in the analysis, but residual confounding is still possible. These limitations, however, 
are inherent to the design of a continent-wide multicenter observational study subject to different local 
guidelines for the management of chronic HIV infection. Nevertheless, results from the multivariable Cox 
proportional hazard model were adjusted by clinical sites.  
Despite limitations, the key strengths of our study are the inclusion of an unselected population of HIV-
infected individuals routinely seen for care across Europe and the fact that we show robust estimates of 
the rates of treatment failure up to five years after the date of initiation. Our results suggest that in routine 
clinical practice, DRV/r-based regimens are independently associated with less risk of experiencing VF and 
any discontinuation or toxicity, showing a higher long-term effectiveness than that of ATZ/r- and LPV/r-
based regimens, especially in ART-experienced patients. Findings from this study may be reasonably 
extrapolated to people living with HIV infection in European and other developed countries. Moreover, 
from the point of view of the new 90-90-90 WHO targets, our findings suggest that DRV/r-containing 
regimens may be considered a preferred PI/r option relative to other PI/r. DRV/r, however, is the most 
expensive PI currently available. Therefore, policies to reduce DRV/r cost and improve its accessibility in 
developing countries are still necessary.  
In summary, assuming no unmeasured confounding factors, the long-term effectiveness of boosted PI-
containing regimens in ART-experienced subjects appears to be greater in people receiving DRV/r than in 
those receiving ATZ/r and LPV/r. The same tendency was observed in ART-naïve patients, although the 
analysis was likely to be underpowered in this population. Strategies to improve clinical care and 
treatment response continue to be necessary in some subsets of the HIV-infected population such as 
women, intravenous drug users, hepatitis co-infected and ethnic minorities.   
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